AUSTIN, Texas--(BUSINESS WIRE)--Asuragen Pharmacogenomic Services, a division of Asuragen, Inc. (Austin, Texas), has entered into a research collaboration with Merck & Co., Inc. to develop a biomarker and pharmacogenomic test for cancer clinical trials. Under the terms of the agreement, Asuragen will apply the information gained from an expression signature identified by Merck’s oncology research program to the development of a diagnostic assay for use in Merck’s cancer clinical trials and to potentially form the basis for commercial companion diagnostic tests for oncology therapies.
